GEA
BIB icon

Glen Eagle Advisors’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Glen Eagle Advisors’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-15
Closed -$781 – 1030
2023
Q2 		$781 Hold
15
– – ﹤0.01% 977
2023
Q1 		$813 Hold
15
– – ﹤0.01% 969
2022
Q4 		$866 Hold
15
– – ﹤0.01% 1036
2022
Q3 		$715 Hold
15
– – ﹤0.01% 1000
2022
Q2 		$726 Hold
15
– – ﹤0.01% 922
2022
Q1 		$930 Hold
15
– – ﹤0.01% 875
2021
Q4 		$1.22K Buy
+15
New +$1.28K ﹤0.01% 852

Other funds holding BIB

CCWM
Cassaday & Co Wealth Management Mclean, Virginia $4.69B AUM 20.56% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $7.5B AUM 33.9% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return

Glen Eagle Advisors's BIB Position: Q3 2023 in Review

Glen Eagle Advisors sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q3 2023, closing a stake of 15 shares — an estimated $781 sold.

Glen Eagle Advisors first reported a position in BIB in Q4 2021 and held it in 7 quarters. The position peaked at $1.22K in Q4 2021. 21 funds tracked by Wall St. Rank hold BIB as of Q3 2023.

  • Glen Eagle Advisors reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q3 2023 after selling out during the quarter.
  • Glen Eagle Advisors sold 15 ProShares Ultra NASDAQ Biotechnology shares in Q3 2023, an estimated $781.
  • Glen Eagle Advisors first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2021 and held it in 7 quarters.
  • Glen Eagle Advisors's ProShares Ultra NASDAQ Biotechnology position peaked at $1.22K in Q4 2021.
  • 21 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q3 2023.

Based on Glen Eagle Advisors's 13F filing for Q3 2023, filed 13 Aug 2024.